FDA Approved: DELSTRIGO — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for DELSTRIGO, Merck's fixed-dose combination HIV-1 therapy (doravirine/lamivudine/tenofovir disoproxil fumarate).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• DELSTRIGO (DORAVIRINE, LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE)

Snippet

SUPPL AP for DELSTRIGO (DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE)